8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Whole Body / General

Bhandari M, Anand AS, Verma K, Regmi K, Amitabh, Prasad DN, Kohli E

Bioeffects Seen

Authors not listed · 2025

Share:

Underpowered studies cannot definitively prove safety - a principle that applies equally to EMF research.

Plain English Summary

Summary written for general audiences

This large randomized trial tested whether adding oral antiviral drugs (molnupiravir or nirmatrelvir-ritonavir) to standard care improved outcomes for hospitalized COVID-19 patients. Neither antiviral showed benefit, with identical 17-19% death rates in both treatment and control groups. The study was stopped early due to low enrollment, limiting the ability to detect smaller benefits.

Why This Matters

While this study focuses on COVID-19 treatments rather than EMF exposure, it demonstrates something crucial about health research that applies directly to EMF science: the importance of adequate sample sizes and the danger of drawing conclusions from underpowered studies. The researchers honestly acknowledged that low recruitment meant they "could not rule out a clinically meaningful benefit" - a level of scientific humility often missing from EMF research discussions. This mirrors challenges in EMF health studies, where industry-funded research frequently uses sample sizes too small to detect real effects, then claims "no evidence of harm." The reality is that many EMF studies suffer from similar power limitations, making it essential to look at the totality of evidence rather than individual underpowered trials when assessing EMF health risks.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2025). Bhandari M, Anand AS, Verma K, Regmi K, Amitabh, Prasad DN, Kohli E.
Show BibTeX
@article{bhandari_m_anand_as_verma_k_regmi_k_amitabh_prasad_dn_kohli_e_ce3169,
  author = {Unknown},
  title = {Bhandari M, Anand AS, Verma K, Regmi K, Amitabh, Prasad DN, Kohli E},
  year = {2025},
  doi = {10.1016/s1473-3099(25)00093-3},
  
}
DOI: 10.1016/s1473-3099(25)00093-3PubMed: 40383127

Quick Questions About This Study

The trial was stopped due to low recruitment. Only 923 participants joined the molnupiravir comparison and 137 joined the nirmatrelvir-ritonavir comparison, far fewer than needed for definitive conclusions about treatment effectiveness.
No significant reduction was found. Death rates were identical at 17% for both molnupiravir-treated patients and those receiving usual care alone. The hazard ratio was 0.93, indicating no meaningful difference.
The study found no benefit. Death rates were identical at 19% for both nirmatrelvir-ritonavir and usual care groups. However, the very small sample size (137 total participants) limited statistical power.
Yes, more than three-quarters of participants were vaccinated and had antispike antibodies at randomization. Additionally, more than two-thirds were already receiving other SARS-CoV-2 antiviral treatments alongside the study drugs.
No. The researchers acknowledged that low recruitment meant "a clinically meaningful benefit of treatment could not be ruled out," especially for nirmatrelvir-ritonavir. Larger studies would be needed for definitive safety conclusions.